Acute transient pain, associated with negligible tissue damage, serves as a physiological warning of potential tissue damage. Somewhat more persistent pain, associated with hyperalgesia and tenderness, is often associated with inflammation. This is also a normal protective response to mild injury and resolves rapidly once the injury has healed. However there are various persistent pain conditions in which the stimulus and pain are unrelated. Thus the pain sensation outlasts its biological usefulness. In these conditions pain can no longer be regarded as a purely physiologically protective symptom. This may arise as a result of chronic pathological lesions or degenerative processes, but in many cases there may be no discernible pathology. These types of chronic pain state-which occur with migraine, rheumatoid arthritis, osteoarthritis, low back pain, cancer pain, and neuropathic pain-are poorly understood and for the most part difficult to treat. Thus chronic pain sufferers of one kind or another account for approximately 10-20% of the adult population, while about 5-8% experience pain which is inadequately treated.'
Present treatment for most pain states has relied heavily on the use of non-steroidal antiinflammatory drugs (NSAID) and opioid analgesics. Although variants of these classes of drug have been developed there has been little conceptual innovation in analgesia for many years. Furthermore both classes of drug produce side effects, such as gastrointestinal disturbances, gastric ulceration, renal damage, and hypersensitivity reactions with NSAID, and nausea, constipation, confusion, respiratory depression, and possibly dependence with opioids. Despite considerable effort these problems have not yet been overcome. An important reason for this has been the relatively slow advance, until recently, in understanding the pathogenesis of chronic pain. Some of these advances have been reviewed and are leading a conceptual shift in pain pathophysiology and management. In the light of this we shall discuss some recent initiatives for the discovery and development of new analgesic drugs based on knowledge of the pathophysiological and neurochemical changes that occur in the nociceptive pathway after injury.
Kinin receptor inhibition Kinins are a family of small peptides which are produced locally in response to tissue injury or trauma and particularly during inflammation.
The two most studied of these are bradykinin and kallidin, a nonapeptide and a decapeptide respectively. Both are cleaved from precursor molecules following the activation of a biochemical cascade. In the plasma, bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) is produced from high molecular weight kininogen (HMWK) whereas in tissue kallidin (lysyl-bradykinin) is liberated from its precursor, low molecular weight kininogen (LMWK)4 by the action of proteolytic enzymes (fig 1) .
Both bradykinin and kallidin are rapidly degraded by peptidases known as kininases giving rise to inactive metabolites with the exception of des-Arg9bradykinin or desArg'0kallidin which lack the carboxy-terminal arginine. These are the only metabolites of bradykinin or kallidin with significant activity.4
Bradykinin and kallidin mediate their effects through two main classes of receptor, B1 and B2.' The genes for both of these receptors have recently been cloned and have been shown to belong to the superfamily of receptors of G protein coupled, 7-transmembrane spanning domains receptors.6 7 Less is known about the molecular characteristics of the B1 receptor but it has little homogeneity with the B2 receptor8 and in keeping with current pharmacological studies it seems likely that antagonists for this receptor will be different from those developed at B2 sites.
Bradykinin and kallidin acts preferentially on the B2 receptor, and this accounts for the majority of the acute pharmacological effects of bradykinin. The preferred agonists for the B1 receptor, however, are the active metabolites, des-Arg'bradykinin and desArg'0kallidin.
Bradykinin exerts a variety of effects on many body tissues but it is its actions on nociceptive neurones that are of most relevance to pain and analgesia. Bradykinin has two main effects on these neurones-activation and sensitisation-and both of these actions have been shown to be mediated primarily by the B, receptor.
Bradykinin depolarises sensory neurones by activation of phospholipase C and stimulation of protein kinase C, with an increase in membrane sodium ion conductance.9 '0 This probably underlies the overt pain response to bradykinin. With respect to sensory neurone activity, bradykinin has been shown to increase nociceptor C fibre discharge in somatic and visceral sensory neurones both in vitrol' 1' and in vivo." In addition to the development of NSAID with COX 2 selectivity there is the possibility that some of the NSAID may have an analgesic action distinct from inhibition of prostanoid synthesis. A recent study has suggested that diclofenac maybe have an anti-hyperalgesic action through the downregulation of sensitised nociceptors, possibly through the nitric oxide-cGMP system.4' Further work is needed to establish whether it would be possible to develop NSAID which effectively reverse nociceptor sensitisation without inhibition of prostaglandin production.
Nitric oxide synthase inhibition
In the last few years there has been great interest in the physiology and pharmacology of nitric oxide (NO). This small gaseous molecule is generated from L-arginine by nitric oxide synthase (NOS) activity.4' Once generated, NO acts as an intercellular messenger, diffusing to its target tissue, and stimulates soluble guanylate cyclase, thus increasing cGMP levels. The increased intracellular concentration of cGMP then regulates a variety of intracellular enzymes including protein kinases and phosphodiesterases.
Nitric oxide synthase, like cyclo-oxygenase, has also been shown to exist primarily in two forms, a calcium-calmodulin dependent enzyme which is expressed constitutively in neuronal and other tissues (cNOS) and an inducible form of the enzyme (iNOS), the activity of which is calcium independent. In addition, however, there are two isoforms of cNOS, so Figure 3 The two isoforms of cyclo-oxygenase subserve different functions within the body. COX-1 is the constitutive enzyme and is involved in normal, physiological regulatory processes such as signal transduction. COX-2 is induced in immunocompetent cells following trauma andlor damage and has a role in the generation and maintenance of inflammation. Existing NSAID (eg, aspirin, ibuprofen) inhibit both isoforms of the enzyme but it is their action on COX-1 that is thought to result in renal and gastric toxicity. The induction or activity of COX-2 can be blocked by dexamethasone and, more recently, by specific inhibitors of this enzyme. Such compounds have been developed with the expectation that they will be anti-inflammatory but devoid of the toxic side effects seen with existing cyclooxygenase inhibitors.
L-NG-monomethyl arginine (LNMMA), or compounds which increase NO levels such as L-arginine and sodium nitroprusside.43 Neither L-NAME nor L-NMMA, however, discriminate between neuronal and endothelial nitric oxide synthase. Recently, a novel inhibitor of nitric oxide synthase, 7-nitroindazole, has been described which shows selectivity for the neuronal form of the enzyme.50 This agent has been shown to be anti-nociceptive in mice at doses that have no effect on blood pressure or vascular smooth muscle in vitro.0 This raises the possibility that a nitric oxide synthase inhibitor could be developed that is anti-nociceptive but devoid of cardiovascular side effects.
There are many studies supporting a role for NO in nociception but the precise involvement is not yet clear. NO is pro-nociceptive in animal models of hyperalgesia. and inhibitors of nitric oxide synthase are antinociceptive against thermal and chemical stimuli. Thus L-NAME, but not its inactive isomer D-NAME, reversed formalin induced foot licking and acetic acid induced writhing in mice and carrageenin induced thermal hyperalgesia in rats. These effects were reversed by the NO precursor L-arginine.5'-55 NO does not, however, appear to be involved in the mechanical hyperalgesia as L-NAME has no effect in carrageenin induced hyperalgesia.55 However NO has also been shown to be involved in thermal hyperalgesia in neuropathic pain in the rat. 56 In addition, L-NAME reduced the ongoing discharge seen in dorsal root ganglia in rats following a peripheral nerve injury. This suggests a role for NO in the maintenance of spontaneous pain following neuropathic lesions.57 Although there are few studies relating to NO and pain in man, a recent report showed that NO was algesic when injected intracutaneously.5" Although the bulk of the evidence supports a pro-nociceptive role for NO there are also reports suggesting an anti-nociceptive action for this mediator. Most of this evidence relates to the administration of the precursor for NO, L-arginine. Thus, L-arginine has been shown to be anti-nociceptive when given centrally or peripherally, possibly through an endogenous opioid action as its actions were An additional complication lies in the specificity of some of the pharmacological tools used to manipulate NO levels. In particular, L-arginine, which is used to raise NO concentrations in many studies, may also be effective as a precursor of kyotorphin which is a substance reported to be an endogenous Metenkephalin releaser.62 Increasing NO levels within the CNS by the use of L-arginine may therefore also increase the levels of this endogenous opioid. Such a mechanism may contribute to the reported anti-nociceptive actions of L-arginine, particularly where there is evidence for an opioid involvement in this phenomenon.59 61 In summary, the evidence relating NO to nociception suggests a complex interrelationship between it and other mediators involved in the generation and maintenance of hyperalgesia. The development of inhibitors which are more selective for the neural form of nitric oxide synthase, including ones which are restricted in their action to the periphery, will aid in clarifying the role of NO in nociception.
Capsaicin analogues Capsaicin is the major pungent extract from hot peppers of the capsicum family. It has the unique property of selectively activating polymodal nociceptors following local or systemic administration. It has long been established that large systemic doses of capsaicin in the neonatal and adult animal are neurotoxic to small unmyelinated Cfibres6" and these high dose treatments lead to a very long lasting or even permanent increase in nociceptive thresholds. However, lower doses of capsaicin result in an acute reversible antinociceptive effect, distinct from the toxic effects seen with much higher doses.6566
The pharmacological and physiological basis for the acute antinociceptive activity remains unclear but may well be related to the action of capsaicin on neuronal ion channels. In particular, activation of cation specific ion channel causes initial depolarisation followed by an inactivation of voltage gated calcium channels and a subsequent reduction of calcium coupled neurochemical release from either the peripheral or central terminals of the sensory neurones.67 Such a mechanism may underlie the short lasting (two to four hour) antinociceptive and anti-inflammatory actions of capsaicin observed with acute systemic applications. With higher or more prolonged administration of capsaicin other mechanisms may be responsible for the loss of sensitivity to both capsaicin and other stimuli, probably involving receptor desensitisation, an impairment of signal transduction, or conduction block in the sensory nerve fibre, or a combination of these.'M 68 It is likely that capsaicin acts on a specific receptor, localised to sensory neurones, and studies with the first competitive capsaicin antagonist, capsazepine, have supported this hypothesis.69
The anti-nociceptive properties of capsaicin, together with its selectivity for polymodal nociceptors, have made it of particular interest to those studying pain mechanisms and as a possible target for future drug development.'
Locally applied capsaicin has been used clinically to alleviate painful conditions such as postmastectomy pain, reflex sympathetic dystrophy pain, diabetic neuropathy, and postherpetic neuralgia.7""7 However, the usefulness of capsaicin itself in these conditions is severely limited by the initial burning sensation experienced with this compound, which can be severe enough to lead to patients discontinuing the treatmnent. It has therefore been challenging to separate the excitatory and pungent actions from the antinociceptive properties, and indeed analogues of capsaicin such as NE19550 and NE21610 have been shown to have less agonistic activity7475 and yet retain analgesic as well as antiinflammatory activity. It therefore seems likely that capsaicin analogues with desirable features can be developed into analgesics of the future (fig 4) .
Tachykinin receptor antagonism Among the most extensively studied of the potential nociceptive mediators within the CNS are tachykinins, a class of neuropeptides including substance P, neurokinin A, and neurokinin B. Of these, substance P has been most extensively investigated with respect to nociceptive mechanisms. There are three receptor types, NK-1, NK-2, and NK-3; substance P acts preferentially on the NK-1 receptor.76 Substance P is located in sensory neurones and is released from their central terminals in the superficial laminae in the dorsal hom of the spinal cord.77 It both directly depolarises dorsal hom neurones and enhances the responsiveness of cells in the dorsal horn to an excitatory amino acid, NMDA, known to be involved in the transmission of nociceptive information. In particular, the phenomenon known as "wind up", characterised by an increase in the excitability of dorsal horn neurones following repetitive C fibre stimulation, is reduced by NK-1 receptor antagonists, suggesting that substance P is involved in the underlying mechanism. 78 The pharmacology of tachykinins with respect to nociception appears to differ between acute and persistent nociceptive conditions. In acute nociception, NK-2 receptors appear to be the predominant receptor involved, with the endogenous mediator being NKA rather than substance P. Thus NK-1 antagonists are less effective in acute nociceptive models than NK-2 receptor antagonists such as MEN10376 and L659874.7879 In persistent inflammatory hyperalgesia, however, it is substance P acting on the NK-1 receptor that is primarily involved, with a corresponding upregulation of mRNA for this receptor subtype.
An important advance in this field has been the development of non-peptide antagonists for tachykinin receptors, particularly the NK-1 subtype. In functional tests these antagonists, such as CP96345 and RP67580, are anti-nociceptive in models of persistent hyperalgesia. 80 It may prove impossible to separate the undesirable side effects of centrally active NMDA antagonists from their anti-nociceptive properties, but if this can be achieved there is the prospect of a novel class of analgesics with efficacy in both acute and chronic pain. On the other hand further work is needed to characterise the peripheral EAA receptors and to develop novel antagonists without the associated side effects seen with centrally acting agents.
In conclusion, great progress has been made in understanding the changes occurring in nociceptive pathways during chronic pain conditions. This has caused a fundamental shift in the way that pain therapy and the development of analgesic drugs are being directed. Mechanistic studies have brought to light a number of new targets both in the periphery (B1 receptors, COX-2, nitric oxide synthase) and in the CNS (nitric oxide synthase, NMDA, tachykinin receptors). This has stimulated the development of antagonists for specific kinin receptors, selective COX-2 inhibitors, and capsaicin analogues which block the activity in fine afferent fibres. In the CNS, there are various opportunities to develop NK1 receptor antagonists and to overcome the difficulties associated with the present generation of NMDA antagonists. Such developments will inevitably supplement or replace the traditional use of NSAID and opioids in the treatment of pain analgesia. 
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